New Cancer Vaccine Shows Promise for Patients with High-Risk Melanoma

Published 2026-11-01

An experimental cancer vaccine based on mRNA technology has helped people with high-risk melanoma, a serious type of skin cancer, to live longer without the disease, according to drug companies involved in the research. The news was reported by 1News, a New Zealand news outlet, and it has attracted attention from medical experts and patients who are waiting for new treatments.

The vaccine uses messenger RNA, the same basic technology that was used in some COVID-19 vaccines. Instead of protecting people from a virus, however, this vaccine is designed to train the body's immune system to recognise and attack cancer cells. Doctors hope that this approach will help the immune system fight the disease more effectively than traditional treatments alone.

Melanoma is one of the most dangerous forms of skin cancer, and it is a concern in New Zealand, which has one of the highest rates of skin cancer in the world. Patients with high-risk melanoma often face a higher chance of the cancer returning after surgery, so new treatment options are important for them and their families.

The vaccine is still in the experimental stage, which means it has not yet been approved for general use. Further testing and larger studies will be needed before it can become available to patients. For now, the results offer hope to people living with melanoma and to the medical researchers who are working to find better ways to treat cancer.

Sources: 1News

More New Zealand news

All New Zealand news · News by country